1 of 1
Story summary
- The AI sector is moving from theory to practical applications, attracting significant investments in implementation-capable companies.
- Investment activity rose 20% year-on-year, with state-owned capital now making up over 68% of total fundraising.
- The biopharmaceutical industry is using AI to cut drug development timelines from years to months.
- Entrepreneurs and investors are prioritizing sustainable growth rates of 20%-30% over high valuations.
- Record fundraising for AI startups has raised concerns about potential market bubbles among industry leaders.
